Intra-Cellular Therapies Company Profile (NASDAQ:ITCI)

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its earnings results on Wednesday, May, 10th. The company reported ($0.62) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.74) by $0.12. The business had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.02 million. During the same period in the prior year, the business posted ($0.64) EPS. View Intra-Cellular Therapies' Earnings History.

9 brokerages have issued 1 year price objectives for Intra-Cellular Therapies' stock. Their forecasts range from $10.00 to $75.00. On average, they anticipate Intra-Cellular Therapies' share price to reach $33.14 in the next year. View Analyst Ratings for Intra-Cellular Therapies.

Here are some recent quotes from research analysts about Intra-Cellular Therapies stock:

• 1. According to Zacks Investment Research, "Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York. " (5/16/2017)
• 2. Cantor Fitzgerald analysts commented, "March FDA meeting could highlight path forward. Management noted that a meeting with the FDA is planned for late March, at which submission of the NDA will be discussed. We expect the company to have no specific commentary until the meeting minutes have been reviewed. If a plan to file is announced, we believe the market could de-risk the program to a level lower than that after the first Phase 3 trial data were released. Key to FDA approval will clearly be the robustness of the data presented to the Agency. The track record for schizophrenia drug programs is that not all trials are successful. Third Phase 3 bipolar depression trial in the works. Management noted that a third Phase 3 trial in bipolar depression will be conducted to optimize potential success." We believe such a strategy makes sense considering that, like schiophrenia clinical trials, some failure is not unusual. With an extra" clinical trial ongoing, were one to fail, we believe it reasonable that an NDA would still be filable. Enrollment is expected to complete by the end of 2018." (3/2/2017)
• 3. Cowen and Company analysts commented, "Today ITCI reported 4Q16 results." (3/1/2017)
• 4. Piper Jaffray Companies analysts commented, "With Intra-Cellular's 4Q16 call set for Weds., 3/1, we're refreshing our thesis and outlining potential outcomes of this business update. Given the 5 months since data, we'll look for visibility on four key issues: 1. Data-driven insight into factors contributing to the 302 trial failure; 2. Preliminary feedback from the FDA on the 302 trial and lumateperone (ITI-007) program; 3. The clinical and regulatory path forward for luma' over the next 12-18 months; 4. Cash required to execute on these plans." (2/23/2017)

Intra-Cellular Therapies saw a decline in short interest in the month of March. As of March 31st, there was short interest totalling 4,612,983 shares, a decline of 9.9% from the March 15th total of 5,119,596 shares. Based on an average daily volume of 626,892 shares, the short-interest ratio is currently 7.4 days.

Some companies that are related to Intra-Cellular Therapies include Forward Pharma A/S (FWP), ZIOPHARM Oncology (ZIOP), Aimmune Therapeutics (AIMT), Alder Biopharmaceuticals (ALDR), Cellectis SA (CLLS), Five Prime Therapeutics (FPRX), Immunomedics (IMMU), Ascendis Pharma A/S (ASND), Esperion Therapeutics (ESPR), TG Therapeutics (TGTX), Albany Molecular Research (AMRI), Aduro BioTech (ADRO), La Jolla Pharmaceutical Company (LJPC), Acorda Therapeutics (ACOR), Omeros (OMER), Keryx Biopharmaceuticals (KERX), MacroGenics (MGNX) and Anika Therapeutics (ANIK).

Intra-Cellular Therapies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (6.32%), BB Biotech AG (4.43%), State Street Corp (2.10%), Clough Capital Partners L P (2.07%) and Morgan Stanley (0.99%). Company insiders that own Intra-Cellular Therapies stock include Alafi Capital Co Llc, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Lawrence P Wennogle, Michael Halstead and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

Intra-Cellular Therapies' stock was sold by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Columbus Circle Investors, Weiss Multi Strategy Advisers LLC, State Street Corp, Morgan Stanley, JPMorgan Chase & Co., Credit Suisse AG and Teachers Advisors LLC. Company insiders that have sold Intra-Cellular Therapies stock in the last year include Kimberly E Vanover, Lawrence J Hineline, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

Intra-Cellular Therapies' stock was purchased by a variety of institutional investors in the last quarter, including Clough Capital Partners L P, BB Biotech AG, Renaissance Technologies LLC, DekaBank Deutsche Girozentrale, Vanguard Group Inc., First Midwest Bank Trust Division, C WorldWide Group Holding A S and Dimensional Fund Advisors LP. Company insiders that have bought Intra-Cellular Therapies stock in the last two years include Alafi Capital Co Llc and Christopher D Alafi. View Insider Buying and Selling for Intra-Cellular Therapies.

Shares of Intra-Cellular Therapies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Intra-Cellular Therapies stock can currently be purchased for approximately $10.60.